Table 4.
Grade III and IV toxicities observed in the phase III study of ranpirnase vs doxorubicin in MMe (according to the National Cancer Institute of Canada [NCIC] classification) (Vogelzang 2000)
|
Ranpirnase |
||||
|---|---|---|---|---|
| G3 | G4 | |||
| Toxicity | no. | % | no. | % |
| Asthenia | 9 | 10.8 | 1 | 1.2 |
| Arthralgia/myalgia | 4 | 4.8 | 0 | 0 |
| Paresthesias | 4 | 4.8 | 0 | 0 |
| Dyspnea | 4 | 4.8 | 0 | 0 |
| Edema | 2 | 2.4 | 0 | 0 |
| Anaphylactoid reaction | 0 | 0 | 1 | 1.2 |
| Nausea and vomiting | 0 | 0 | 1 | 1.2 |
|
Doxorubicin |
||||
|---|---|---|---|---|
| G3 | G4 | |||
| Toxicity | no. | % | no. | % |
| Asthenia | 2 | 4.5 | 0 | 0 |
| Fever | 2 | 4.5 | 1 | 2.3 |
| Anorexia | 1 | 2.3 | 0 | 0 |
| Mucositis | 1 | 2.3 | 0 | 0 |
| Nausea and vomiting | 1 | 2.3 | 1 | 2.3 |